Mid-sized biopharma companies are under growing pressure to accept most-favored nation drug pricing deals with the White House. On the latest BioCentury This Week podcast, BioCentury&#x27;s analysts assess the trade-offs companies face, the litigation risks around mandatory Medicare MFN pricing demonstrations, and what happens to companies that don&#x27;t sign on. The analysts also discuss Eli Lilly&#x27;s acquisition of Merida, its thirteenth takeout of the year, Heidi Overton&#x27;s nomination as FDA commissioner and what it signals about FDA independence, and Revolution Medicines&#x27; 35-day filing-to-approval timeline under FDA&#x27;s national priority review voucher pilot. View full story: https://www.biocentury.com/article/660655 #DrugPricing #FDA #BiotechMA #Oncology #BiopharmaPolicy 0:00 - Introduction 2:14 - MFN Drug Pricing Deals 10:09 - Lilly Acquires Merida 22:22 - FDA Commissioner Pick 30:11 - RevMed&#x27;s Rapid Approval To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

Ep. 385 - MFN deals, Lilly takeout, FDA pick Overton

BioCentury This Week

Mid-sized biopharma companies have been pressured to accept most favored nation drug pricing deals with the White House. That's the MFN initiative of the Trump administration that 17 pharma companies have already signed up for. We'll break down the latest for you on this week's BioCentury This Week podcast.

And Eli Lilly is at it again, this time buying Merida, a well-financed startup out of Cambridge, Mass. that's been developing therapeutics for serious autoimmune and allergic diseases, including Graves' disease. And the biggest issue about Heidi Overton, the White House's pick for FDA Commissioner,

isn't her resume or even her ties to the Trump administration. It is how she will approach the job. Steve Usdin is back from vacation and will tell you all about what you need to know with what's happening at FDA. And finally, RevMed's pancreatic therapy is here.

The approval showed FDA racing to make its decision on a first-in-class therapy. But how does the speed of this decision stack up against other rapid FDA decisions? I'm Jeff Cranmer, host of the BioCentury This Week podcast. And in addition to Steve Ustin, also joining me, editor-in-chief Simone Fishburn,

Lindsay Martin, our biopharma analyst, and Josh Berlin, our head of business development. Steve, how was the vacation? It was great. I don't know why I came back. But yes, I do know why I came back. I came back to talk to you about MFN and Heidi Overton and other things. Excellent. MFN, of course, for those who don't know the lingo, though I'm pretty sure most people do now,

Ep. 385 - MFN deals, Lilly takeout, FDA pick Overton

Read the full transcript

The candid version is on a podcast,
not the earnings call.

Ep. 385 - MFN deals, Lilly takeout, FDA pick Overton

Read the full transcript

The candid version is on a podcast, not the earnings call.

The candid version is on a podcast,
not the earnings call.